Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.

Latest From Sten Stovall

Roche Deals With Huge Gantenerumab Curiosity At H1 Update

Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.

Sales & Earnings Neurology

Anocca To Reach Clinical-Stage With T-Cell Therapies After After Series B Injection

Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip

Clinical Trials Commercial

Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid

Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.

Clinical Trials StartUps and SMEs

Pipeline Catalysts Key Focus For Roche’s H1 Update

Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.

Sales & Earnings Companies

Regeneron Lifts Stake In Biotech Partner ISA Pharma

Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.   

Clinical Trials Commercial

Small Swedish Biotech Cyxone’s US CEO Has ‘Big Plans’

Swedish biotech Cyxone’s CEO tells Scrip about its aims to become a cutting-edge developer of disease-modifying treatments for rheumatoid arthritis and multiple sclerosis, but says the Scandinavian industry needs a ‘mindset change’.

Clinical Trials Commercial
See All
UsernamePublicRestriction

Register